156 related articles for article (PubMed ID: 20134269)
1. Metastatic uterine leiomyosarcomas: a single-institution experience.
Bernstein-Molho R; Grisaro D; Soyfer V; Safra T; Merimsky O
Int J Gynecol Cancer; 2010 Feb; 20(2):255-60. PubMed ID: 20134269
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S; Dizdar O; Karakas Y; Turker A; Kars A
Curr Probl Cancer; 2018; 42(3):344-349. PubMed ID: 29576383
[TBL] [Abstract][Full Text] [Related]
3. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
4. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
5. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.
Hoang HL; Ensor K; Rosen G; Leon Pachter H; Raccuia JS
Int J Surg Oncol; 2014; 2014():919323. PubMed ID: 25045534
[TBL] [Abstract][Full Text] [Related]
7. Uterine leiomyosarcoma: analysis of treatment failures and survival.
Gadducci A; Landoni F; Sartori E; Zola P; Maggino T; Lissoni A; Bazzurini L; Arisio R; Romagnolo C; Cristofani R
Gynecol Oncol; 1996 Jul; 62(1):25-32. PubMed ID: 8690287
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant treatment on oncologic outcomes in patients with stage I leiomyosarcoma of the uterus.
Boyraz G; Başaran D; Salman MC; Özgül N; Yüce K
Turk J Med Sci; 2017 Jun; 47(3):841-846. PubMed ID: 28618731
[TBL] [Abstract][Full Text] [Related]
9. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?
Worhunsky DJ; Gupta M; Gholami S; Tran TB; Ganjoo KN; van de Rijn M; Visser BC; Norton JA; Poultsides GA
J Surg Oncol; 2015 Jun; 111(7):808-12. PubMed ID: 25920434
[TBL] [Abstract][Full Text] [Related]
10. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis.
Leitao MM; Zivanovic O; Chi DS; Hensley ML; O'Cearbhaill R; Soslow RA; Barakat RR
Gynecol Oncol; 2012 May; 125(2):409-13. PubMed ID: 22366592
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
[TBL] [Abstract][Full Text] [Related]
12. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
13. Treatment of uterine leiomyosarcoma.
Berchuck A; Rubin SC; Hoskins WJ; Saigo PE; Pierce VK; Lewis JL
Obstet Gynecol; 1988 Jun; 71(6 Pt 1):845-50. PubMed ID: 2453004
[TBL] [Abstract][Full Text] [Related]
14. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Wien Klin Wochenschr; 2004 Feb; 116(4):135-9. PubMed ID: 15038405
[TBL] [Abstract][Full Text] [Related]
16. Does Lymphadenectomy Improve Survival in Uterine Leiomyosarcoma?
Tasci T; Karalok A; Taskin S; Ureyen I; Kımyon G; Tulek F; Ozfuttu A; Turan T; Tulunay G; Kose MF; Ortac F
Int J Gynecol Cancer; 2015 Jul; 25(6):1031-6. PubMed ID: 25853382
[TBL] [Abstract][Full Text] [Related]
17. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.
Clavero JM; Deschamps C; Cassivi SD; Allen MS; Nichols FC; Barrette BA; Larson DR; Pairolero PC
Ann Thorac Surg; 2006 Jun; 81(6):2004-7. PubMed ID: 16731120
[TBL] [Abstract][Full Text] [Related]
18. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
19. Leiomyosarcoma of the uterus: case reports and a review.
Gallup DG; Cordray DR
Obstet Gynecol Surv; 1979 Apr; 34(4):300-12. PubMed ID: 471365
[TBL] [Abstract][Full Text] [Related]
20. Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature.
Sandruck J; Escobar P; Lurain J; Fishman D
Gynecol Oncol; 2004 Feb; 92(2):701-4. PubMed ID: 14766270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
